You just read:

Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe

News provided by

Astellas Pharma Inc.

Aug 28, 2011, 08:00 ET